千红制药(002550) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥338,085,544.70, representing a 38.73% increase compared to ¥243,708,343.81 in the same period last year[8] - The net profit attributable to shareholders was ¥84,075,310.30, up 19.40% from ¥70,416,381.36 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥55,657,921.82, reflecting a 20.14% increase from ¥46,326,348.25 in the previous year[8] - The basic earnings per share increased to ¥0.0660, up 20.00% from ¥0.0550 in the previous year[8] - The company expects net profit attributable to shareholders for the first half of 2018 to be between CNY 158.398 million and CNY 187.198 million, representing a year-on-year increase of 10.00% to 30.00%[23] - The increase in net profit is attributed to continuous growth in sales revenue driven by strengthened domestic and international market expansion[23] Cash Flow - The net cash flow from operating activities was ¥5,755,611.06, a 25.32% increase compared to ¥4,592,606.57 in the same period last year[8] - Net cash flow from investment activities decreased by 55.7% compared to the same period last year, mainly due to a reduction in investment financial products[17] - Net cash flow from financing activities increased by CNY 14.1482 million year-on-year, primarily due to an increase in working capital loans[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,082,873,594.58, a 1.27% increase from ¥3,044,305,214.35 at the end of the previous year[8] - The net assets attributable to shareholders increased by 3.45% to ¥2,521,111,596.71 from ¥2,437,036,286.41 at the end of the previous year[8] - The company experienced a 37.04% decrease in accounts payable, attributed to payments made for previously unpaid project construction costs[16] - The company increased its prepayments for raw materials, resulting in an increase of ¥8,307,600 compared to the beginning of the period[16] Expenses and Charges - The company reported a 49.08% increase in operating costs compared to the same period last year, primarily due to sales growth and rising raw material prices[16] - Tax and additional charges increased by CNY 2.1058 million compared to the same period last year, mainly due to the increase in value-added tax payable[17] - Asset impairment losses increased by CNY 2.6275 million year-on-year, primarily due to the provision for bad debts resulting from increased sales[17] - Other income rose by CNY 5.1937 million compared to the previous year, mainly due to the reclassification of government subsidies related to daily activities from "non-operating income" to "other income" following the revision of accounting standards[17] - Income tax expenses grew by 40.66% year-on-year, primarily due to profit growth[17] Corporate Developments - The company’s self-developed QHRD107 capsule's clinical trial application was accepted by the CFDA in March 2018[18] - The company completed the granting of 100,000 reserved shares under the 2017 restricted stock incentive plan in March 2018[18]